What Can You Expect in 2026?

Join the European hub for proximity-based drug discovery as the 6th TPD & Induced Proximity Summit Europe returns to London. This year’s summit offers a focused, single-track experience that brings together Europe’s most innovative minds working on targeted protein degradation and proximity-based therapeutics. From antibody-based degraders to molecular glues and stabilizers, the program highlights real-world applications and clinical momentum.

Expect a dynamic mix of first-in-human data, biology-first strategies, and deep-dive workshops designed to tackle challenges in oral bioavailability, PK/PD modelling, and target engagement. Hear from leading voices at GSK, Abbvie, Amphista, Autotac Bio, PhoreMost, and the University of Dundee, and connect with over 80 experts driving innovation across oncology, neurodegeneration, and immunology.

Whether you are focused on early discovery or clinical translation, this summit offers the insights and connections to accelerate your proximity pipeline.

Divide-conquer

Unmissable Event Highlights

Charting the Future of Proximity Therapeutics

Professor Ciulli opens the summit with a deep dive into the evolution of targeted protein degradation, sharing new insights into ternary complex formation and the next generation of proximity-based drug design.

Advancing Molecular Glue Mechanisms for Precision Targeting

Explore how molecular glues are being rationally designed to enhance selectivity and therapeutic potential, with cutting-edge research on degradation pathways and screening strategies.

Fuelling Innovation: VC & Pharma Perspectives on European TPD Growth

Gain insider perspectives on how investors and pharma partners are backing proximity-based platforms, structuring collaborations, and identifying the next wave of clinical candidates.

Astellas Pharma
Cambridge Innovation Capital
Epidarex
Pace Ventures
Sofinnova Partners
Hands-On Learning Through Deep-Dive Workshops

Join interactive sessions focused on antibody-based degraders, non-oncology applications, and glueable target identification to expand your modality toolkit.

Abbvie
Ambagon Therapeutics
Autotac Bio
Laigo Bio
Sanofi
Clinical Momentum: First-in-Human Data & Translational Insights

Hear exclusive updates from companies advancing proximity drugs into the clinic, with case studies on PK modelling, dosing strategies, and cross-species validation.

Autotac Bio
Foghorn Therapeutics
Merck

Explore the Full Event Guide

  • 25+ Expert Speakers from Leading Biopharma and Academia
  • 15+ Data-Led Case Studies Showcasing Clinical Updates, Novel Ligases, and Glue Discovery Breakthroughs
  • 8+ Hours of Networking Including Speed Networking, Poster Sessions, and Informal Collaboration
  • 3 Deep-Dive Workshops on Antibody-Based Degraders, Non-Oncology Applications, and Glueable Target Identification
6th TPD & Induced Proximity Summit Europe Full Event Guide

Attending Companies Include

Explore-the-Agenda
Explore the Agenda

Discover the latest breakthroughs in PROTACs, molecular glues, and proximity therapeutics through expert-led sessions and case studies.

Partner-With-Us
Partner With Us

Connect with Europe's leading drug developers seeking discovery platforms, chemistry services, and translational support for TPD programs.

Join-Biopharma-Experts
Join the TPD Community

Network with top scientists and biopharma innovators driving proximity-based drug development across oncology, CNS, and beyond.